FDA grants Priority Review to GW's Epidiolex for seizures

GW Pharmaceuticals plc (NASDAQ:GWPH) said FDA accepted and granted Priority Review to an NDA for Epidiolex cannabidiol as an

Read the full 198 word article

User Sign In